41 results about "Large cell" patented technology

A biomarker for predicting drug resistance of a BTK inhibitor and an application thereof are provided in the present disclosure, relating to the technical field of biomedicine. The biomarker is SMPD1 or SPHK1; the drug resistance of BTK inhibitor refers to the drug resistance of diffuse large B cell lymphom cells to the BTK inhibitor. This biomarker is used to predict sensitivity of diffuse large B cell lymphom cells to the BTK inhibitors.

Aiming at the problem that a conventional mask cannot absorb large cells through natural permeation, the invention provides the preparation method of the nano-microsphere cell active factor mask, and the nano-microsphere cell active factor mask is prepared through the processes of preparing an emulsion system, solidifying small liquid drops, alkalizing materials such as polymer collagen / chitosan microspheres, stirring to prepare a nano-microsphere cell active stock solution and the like. According to the prepared polymer collagen / chitosan porous microspheres, cell active factors are diffused into the pore diameters of the microspheres, the permeability of active factor cells is improved through a microsphere carrier, and proliferation and growth of skin epidermal cells are greatly promoted.

The invention discloses a multi-scale feature fusion cervical abnormal cell detection method, and relates to the technical field of medical image processing and deep learning. Firstly, a cervical lesion cell detection method based on multi-scale feature fusion is used, efficient capture of multi-scale features from local details to an overall structure in a cervical lesion cell image is achieved by providing a CSPM, the CSPM can dynamically extract the features among different scales, context information is fully utilized, and the detection accuracy of the cervical lesion cells is improved. The method comprises the following steps of: firstly, designing a multi-scale fusion attention module, so that the defect of single-scale characteristics in expression capability is overcome, the problems of large cell size change and complex background are effectively solved, secondly, the designed multi-scale fusion attention module further enhances the characteristic fusion capability, and the MSFA can adaptively adjust the weights of different-scale characteristics according to the importance of the cell characteristics, so that the fusion accuracy is improved. And local and global information is fully fused, so that the capability of sensing and identifying the abnormal cervical cells by the network is improved.

The invention discloses application of a mast cell polarization typing detection kit, and belongs to the field of biological medicine. The kit comprises a mast cell characteristic enzyme TPSB2 detection reagent, and one or more of a mast cell MC1 type polarization detection reagent and a mast cell MC2 type polarization detection reagent, the MC1 type polarization is CCL27, and the expression of TNF-alpha is up-regulated; and the MC2 type polarization comprises expression up-regulation of CCL3, IL-16 and VEGFA (vascular endothelial growth factor A). Mstoma cells have dual effects in a tumor microenvironment, can promote tumor progression, and also can enhance anti-tumor immune response. The mastocyte polarization typing is identified through the expression level of the biomarker, so that the mastocyte polarization typing can be rapidly and accurately evaluated, identification indexes and tools are provided for further discussing the functions of mastocytes in different polarization states, cancer diagnosis can be assisted, the onset risk of cancer can be reduced, and the method is suitable for popularization and application. And an immunotherapy target is provided for clinical treatment of cancers.

The invention discloses a flavone composition capable of preventing and improving atopic dermatitis and application of the flavone composition, and belongs to the field of medicines and cosmetics. Cell morphology observation and beta-hexosaminidase detection prove that apigenin and chrysin have a good effect of inhibiting large cell strain degranulation; scratch experiments prove that kaempferol has a good effect of promoting interstitial closure of human keratinocytes, and then detection of atopic dermatitis related factor expression discovers that apigenin, chrysin and kaempferol are compounded to have the potential of enhancing the soothing effect. And human body safety evaluation and efficacy experiments are further carried out to screen out the optimal proportion of the soothing effect. The invention explores the multi-target synergistic prevention and improvement effect of the flavonoid compound on the aspects of allergy resistance, inflammation resistance and barrier repair, and expands the application and development value of the flavonoid compound in soothing cosmetics.

The invention relates to the technical field of neutrophile granulocyte separation, in particular to a mouse neutrophile granulocyte separation method which comprises the following steps: (1) anesthetizing and disinfecting a mouse; (2) tissue sampling; (3) tissue digestion; (4) preparing a cell suspension; (5) purifying cells; (6) cell culture; according to the method disclosed by the invention, isoflurane is adopted in the anesthesia disinfection step, so that central nervous activity of mice can be rapidly inhibited, tissue damage caused by stress reaction is avoided, and chemical stimulation can be reduced while body surface microorganisms are cleared through combination of ethanol disinfection and sterile normal saline flushing, and aortic tissues with intact activity are provided for subsequent material taking. In the compound enzyme digestive juice, collagenase I can specifically degrade aortic wall collagenous fibers, trypsin dissociates adhesion connection between cells, neutral protease assists in decomposing elastic fibers, and DNA enzyme I is supplemented to inhibit cell aggregation, so that the contradiction between incomplete digestion and large cell damage of the traditional enzyme juice is effectively solved.

The present invention discloses a computer device and computer-readable storage medium for identifying or assisting in the identification of large cell transformation of mycosis fungoides. The present invention provides a computer device comprising a memory, a processor, and a computer program stored in the memory, wherein the processor performs the following steps: S1) data reception: receiving the percentage of FOXM1-positive cells in skin lesions of a subject with mycosis fungoides (MF); S2) data output: outputting result information from the computer based on the percentage of FOXM1-positive cells, wherein the result information indicates whether the subject with mycosis fungoides has, or is a candidate for, large cell transformation of mycosis fungoides. Experiments in the present invention demonstrate that immunohistochemical staining for FOXM1 can more accurately locate large cells and quantify the proportion of large cells compared to traditional pathological techniques, thereby reducing subjective bias. Therefore, it is proposed that immunohistochemical staining for FOXM1 can be used as an auxiliary technique for diagnosing large cell transformation of mycosis fungoides.

The invention discloses double-mesoporous silica nanoparticles for modifying ionizable amino and a preparation method and application of the double-mesoporous silica nanoparticles. The core technical process of the double-mesoporous silica nanoparticles comprises the following steps: firstly, synthesizing mesoporous silica through a double-template method of a block copolymer and a surfactant; then grafting ionizable amino to the surface of the mesoporous silica through a silane coupling agent; and finally, RNA is loaded on the modified mesoporous silica by electrostatic adsorption, and efficient tumor treatment is finally realized. The invention also discloses an application of the silicon dioxide nanoparticles in RNA delivery. The silicon dioxide nanoparticles prepared according to the method disclosed by the invention have high RNA loading efficiency and cell uptake efficiency. The double-mesoporous silica nanoparticles modified with ionizable amino groups have the advantages of large drug loading capacity, high cell uptake rate, high biocompatibility, simplicity in synthesis, mild reaction conditions, convenience in cutting and the like, and have a good application prospect.

The invention discloses a stem cell-based microvesicle as well as a preparation method and application thereof, belongs to the technical field of biological tissue engineering, and particularly relates to a preparation method of the stem cell-based microvesicle, which comprises the following steps: culturing stem cells until the cell fusion degree is 80-90%, performing hypoxia treatment, and cleaning for 2-3 times; standing and culturing the cleaned stem cells, then adding a calcium ion carrier, and carrying out ultrasonic treatment; the serum-free basic culture medium containing the calcium ion carrier is immediately absorbed and removed, the cells are cleaned through PBS, culture is conducted for 24 h, and cell supernatant is collected and merged respectively; performing first centrifugation to remove cell debris; performing second centrifugation to remove dead cells and large cell debris; carrying out third centrifugation to remove organelles; fourth centrifugation is carried out, large vesicles are removed, and a final supernatant is obtained; and filtering and centrifuging to obtain a microvesicle precipitate. The preparation method of the microvesicles aims at systematically improving the yield and biological activity of the stem cell microvesicles through low-oxygen pre-stimulation, ultrasonic-calcium ion carrier synergistic induction and differential centrifugation.

The invention discloses a stem cell filtering separator, and relates to the technical field of stem cell treatment.The stem cell filtering separator comprises a bottom plate, two supporting plates are symmetrically and fixedly connected to the side wall of the top end of the bottom plate, separating boxes are fixedly connected to the side walls of the top ends of the two supporting plates, and through holes are formed in the side walls of the top ends of the two separating boxes; and the interiors of the corresponding through holes are fixedly connected with the same liquid inlet pipe. When stem cells are filtered and separated, the blocking condition of the filtering membrane holes can be detected in real time, meanwhile, large cells and cell debris blocked in the filtering membrane holes can be sucked to the position above the partition plate through the connecting pipe, the blocked large cells and cell debris are collected, and the large cells and cell debris can be conveniently filtered and separated. The filtering membrane holes are not blocked by larger cells and cell debris, so that the high efficiency and the reliability of the stem cell filtering and separating device are improved to a great extent when the stem cell filtering and separating device is used for filtering and separating stem cells.

According to the invention, a novel immune checkpoint molecule SIDT1 is found. The SIDT1 is a powerful T cell inhibition factor mainly expressed on CD8 < + > T cells. A series of SIDT1 inhibitors are identified in the invention. The SIDT1 inhibitor can enhance the anti-tumor CD8T cell reaction and limit tumor progression, so that a new thought is provided for treatment and prevention of related tumor patients with PD-1 treatment resistance.

The invention relates to methods for extracting, purifying and concentrating mesenchymal stromal cell exosomes enriched with micro-RNA, proteins and lipids, and can be used in cosmetology and pharmacology for rehabilitation and regeneration. The technical result of the invention is a more efficient process for producing exosomes. This technical result is achieved in that the present method for extracting, purifying and concentrating exosomes from mesenchymal stromal cells includes cultivating cells, collecting the conditioned culture medium, depleting high-molecular-weight proteins, extracting, purifying and concentrating exosomes, and freezing and lyophilizing the exosome concentrate; in order to enrich the culture medium with exosomes, multipotent mesenchymal stem cells (MSCs) are grown in a medium having a lowered glucose concentration and containing platelet lysate and 5 mM of L-alanyl-L-glutamine, wherein, in the case of static cell cultivation, the growth medium is placed in a culture vessel and once a level of not less than 80% monolayer confluence is reached, the culture medium is harvested and replaced once every 24 hours, and in the case of flow-through cell cultivation, cells are placed on cell carriers in a bioreactor and 72-96 hours after the start of cultivation, the culture medium is harvested and replaced once every 24 hours, the exosome-enriched culture medium is subjected to concentration, which includes successive stages of centrifugation, tangential flow filtration and isopycnic centrifugation: in the first stage, the culture medium is centrifuged for 10 mins at 2000 g to remove large cell particles and other inclusions; in the tangential flow filtration stage, the supernatant is concentrated using hollow fibre filters having a molecular weight cutoff of 500 kDa, after which the concentrate is subjected to fivefold diafiltration with an equal volume of DPBS phosphate buffer solution using the same hollow fibre cartridge; and in the isopycnic centrifugation stage, the concentrated supernatant is mixed with a saccharose solution and deuterium oxide and subjected to isopycnic centrifugation at 100000 g and 4˚С for 75 mins, after which the concentrate is subjected to further fivefold diafiltration with a buffer solution, then the concentrate is filtered through filters with a pore diameter of 0.22 µm and 0.1 µm, the exosome concentrate is subjected to initial freezing to -75˚C in a freezing chamber, and drying is carried out in a lyophilization chamber, wherein in a first drying stage, the concentrate is cooled to -40˚С and subsequently held for 100 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -30˚С and subsequently held for 610 mins at an absolute pressure in the chamber of not more than 10 Pa, then cooled to -10˚С and subsequently held for 315 mins at an absolute pressure in the chamber of not more than 10 Pa, after which it is cooled to 0˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa, then heated to +10˚С and subsequently held for 130 mins at an absolute pressure in the chamber of not more than 10 Pa; in a second drying stage, drying is carried out at +22˚С for not less than 130 minutes at an absolute pressure in the chamber of not more than 10 Pa.

Adoptive cell therapy, and related methods, compositions, uses, and articles of manufacture, are provided that include administration of a dose of cells for treating a subject having a particular B cell malignancy. The cells generally express a recombinant receptor, such as a chimeric antigen receptor (CAR). In some embodiments, the disease or condition is large cell type B cell lymphoma (LBCL) that is refractory or relapsed to frontline chemoimmunotherapy.

Provided herein are compositions and methods related to depletion of mast cells using an anti-c-kit antibody. The compositions and methods described herein may be used to treat a subject in need of mast cell depletion due to a variety of diseases or disorders, such as chronic spontaneous urticaria (CSU).

The invention provides a lung adenocarcinoma 2.5 D organ yield-increasing and consumption-reducing production process using a 96-well plate, the process uses a conventional 96-well plate with the diameter of each well less than 1cm to reduce the loss of raw materials, and meanwhile, two new methods suitable for the 96-well plate are provided to increase the diameter and yield of 2.5 D organs. The invention relates to the technical field of organoids, raw material loss is reduced by using a 96-well plate, and the contact opportunity between cells is increased by limiting tumor cells in a narrow space, so that the volume production of 2.5 D organoids of lung adenocarcinoma can be realized. The 96-well plate with a smaller area is used for reducing the loss of raw materials, and meanwhile, the yield and diameter of the organoid can be greatly increased.

The present invention provides a method for preparing a nutritional composition of xenogenic EVs from tissues / organs, comprising steps of collecting tissue / organ sample from fetal or adult mammal (101), keeping the collected sample in buffered saline in cold (102), mincing it into small pieces (103) and then mixing them with collagenase and deoxyribonuclease (104) followed by incubation and agitation (105), filtrating the incubated sample pieces for obtaining a filtrated liquid suspension containing extracellular fluid having EVs (106), differentially centrifuging the liquid suspension to remove remaining cells and tissue debris and obtain a supernatant (107), filtering the supernatant for collecting a crude fraction of large EVs (108) and centrifuging the supernatant for enriching it into a fraction of smaller EVs (109), characterized in that the separated EVs are fetal EV cargo or sinusoidal EVs directly isolated from the collected samples, wherein these EVs have regenerative potency, and the cells remain intact during EV isolation.

This disclosure provides medicaments and methods for treating envenomation using small molecule inhibitors of secretory phospholipase A2 (sPLA2). The sPLA2 inhibitor AZD2716 and related compounds can be used as monotherapy. Alternatively, the sPLA2 inhibitor varespladib and / or methyl varespladib can be used in combination with a statin. When a subject has been envenomed (for example, by a snake bite or bee sting), the medicaments can be administered to prevent lethal effects or tissues damage cause by the venom: for example, acute kidney injury, mast cell degranulation, or cerebral edema. The medicaments may be contained in an automatic injection device or an injection pen to deliver an effective dose as soon as possible following envenomation.

The present application relates to a molecular marker combination and detection reagent for identifying human blood mast cell precursor cells and application, and belongs to the technical field of cell detection. The molecular marker combination can realize efficient identification of human blood mast cell precursor cells, provide a new means for diagnosis of allergic diseases, and provide a new target for intervention of allergic diseases. The present application provides a molecular marker combination for identifying human blood mast cell precursor cells, wherein the molecular marker comprises a human cell surface molecule and a human intracellular molecule, the human cell surface molecule comprises CD34 and Fc epsilon R1 alpha, and the human intracellular molecule comprises CPA3, TPSAB1 and GATA2.

The invention discloses application of MRGPRX2 in diagnosis and treatment of esophageal cancer, and belongs to the field of biological medicine. The application comprises a reagent capable of detecting the MRPGRX2 or the expression quantity of the MRPGRX2, an application of the reagent in preparation of a kit for auxiliary diagnosis of esophageal cancer, or an application of the reagent in screening of potential drugs for treating esophageal cancer. The invention relates to a reagent capable of detecting MRPGRX2 or the expression quantity of MRPGRX2, and application of the reagent in preparation of a reagent for detecting the polarization state of mast cells. The invention relates to an application of a component for inhibiting or blocking MRPGRX2 expression in preparation of a medicine for treating esophageal cancer. The component for inhibiting or blocking the expression of MRPGRX2 is used for preparing a medicine for blocking the promotion effect of mast cells on invasion and migration of esophageal cancer cells. The expression level of MRGPRX2 in mast cells is changed through molecular biology means such as construction of MRGPRX2 specific siRNAs, and it is revealed that M2 polarization of the mast cells can be remarkably inhibited by interfering MRGPRX2 expression, and then tumor cell biological phenotypes such as invasion and migration of esophageal cancer cells are inhibited. Therefore, the MRGPRX2 can be used as a new tumor immunotherapy target to be applied to preparation and screening of drugs for detecting esophageal cancer prognostic markers or inhibiting esophageal cancer invasion and migration, and a new method is provided for prognostic evaluation or treatment of esophageal cancer.

The invention discloses a near-infrared light response fatty acid copper nano-drug as well as a preparation method and application thereof. According to the near-infrared light response fatty acid copper nano-drug, copper nanoparticles serve as a core, the outer layer of the copper nanoparticles is wrapped with a phase-change material organic shell layer, meanwhile, a copper ion carrier is loaded in the organic shell layer, and mitochondrial targeting lipid is modified on the shell layer. The nano-drug constructed by the invention can target tumor cells with high expression of CD36 and increase the dosage in the cells, has good mitochondrial targeting and space-time controllable release characteristics, shows a good photo-thermal treatment effect, can kill the tumor cells more accurately and controllably, and establishes a new strategy for cancer treatment.

Described herein is a method of enriching lymphocytes from a biological sample, the method comprising: (a) removing large cells and small cells from the biological sample by a size based selection method to obtain lymphocytes, wherein the large cells comprise granulocytes or monocytes, or a combination thereof, and the small cells comprise platelets, red blood cells, or a combination thereof; (b) contacting the lymphocytes with an activating agent to obtain activated lymphocytes; and (c) removing inactivated lymphocytes from the activated lymphocytes using a sized based selection method to obtain activated enriched lymphocytes, thereby obtaining enriched activated lymphocytes.

The present application belongs to the technical field of nucleic acid delivery and gene editing, and particularly relates to a method for knocking out a target gene of a cell in vitro by using an LNP delivery system. In view of the technical problems of unstable editing efficiency, large difference in editing efficiency between different individuals, low transfection efficiency, large cell damage, unstable knockout effect and the like when a T cell is transfected by using an existing LNP for gene editing, the present application provides a method for efficiently knocking out a target gene of a T cell in the form of LNP by optimizing the LNP and LNP transfection operation parameters in a systematic manner. The method can effectively solve the above technical bottlenecks, realize efficient and stable knockout of a target gene of a T cell, and provide reliable technical support for T cell function research and immunotherapy application.

According to the present invention, a pharmaceutical composition for preventing and treating lung adenocarcinoma, comprising K-ras-specific activated T cells, is used as an antigen composition designed such that a K-ras mutant (G12D, G12V, and G13D) recombinant overlapping peptide is sequentially divided into a total of 12 epitopes (n=1 to 12, and the last epitope (n=12) consists of 23 amino acids) in units of 30 amino acids in the amino acid sequence of K-ras, and 15 amino acid sequences overlap between the epitopes. Thus, the pharmaceutical composition is more effective in recognizing and killing lung adenocarcinoma in which K-ras, K-ras mutant G12V, K-ras mutant G12D, or K-ras mutant G13D is detected. Therefore, according to the present invention, the pharmaceutical composition for preventing and treating lung adenocarcinoma, comprising K-ras-specific activated T cells, can be used to effectively prevent and treat lung adenocarcinoma, particularly lung large cell adenocarcinoma, in which K-ras as well as K-ras mutants are detected.

The invention relates to the technical field of biological medicine, in particular to a size-limited extracellular vesicle derived from myocardial cells and a preparation method and application thereof. Lipopolysaccharide (LPS) is adopted to stimulate myocardial cells H9C2, the myocardial cells H9C2 are induced to generate myocarditis cells, the extracellular vesicles with the limited size are separated from the myocarditis cells generated through induction by using a differential centrifugation method, and research finds that the extracellular vesicles with the limited size can inhibit macrophages in an inflammatory state from secreting inflammatory factors, so that the extracellular vesicles with the limited size can be used for preparing the anti-inflammatory drug. The macrophages are transformed into an anti-inflammatory repair phenotype (M2). Meanwhile, in a mouse with myocarditis, the large extracellular vesicles can relieve the state of myocarditis and have the effect of relieving myocarditis.

A method for inhibiting the release of tumor necrosis factor (TNF) from mast cells including administering an effective amount of an inhibitor to a subject; wherein the inhibitor is an inhibitor that selectively targets conventional mitogen activated protein kinase signaling pathways; and allowing the inhibitor to interact with mast cells or their signaling pathways involved in TNF release, thereby inhibiting TNF release. Also disclosed is a method for preventing the conversion of membrane-bound tumor necrosis factor (mTNF) to soluble tumor necrosis factor (sTNF) in mast cells using an inhibitor including administering an effective amount of the inhibitor to a subject; wherein the inhibitor is a chemical compound that selectively targets conventional mitogen activated protein kinase signaling pathways; and allowing the inhibitor to interact with mast cells or the enzymatic machinery responsible for the cleavage of mTNF within mast cells, thereby inhibiting the conversion of mTNF to sTNF.

Disclosed are a delivery system based on sensitized mast cells, a preparation method therefor, and an application thereof, as well as a pharmaceutical composition and a drug administration device involving the delivery system of sensitized mast cells. The delivery system utilizes the specific recognition of tumor antigens by sensitized mast cells to targetedly deliver drugs to tumor cells, while protecting the drugs from the clearance of the circulating immune system. Sensitized mast cells rapidly degranulate under the activation of tumor antigens to release drugs, thereby enhancing infection, exerting an oncolytic effect, lysing tumor cells and releasing antigens, and activating an anti-tumor immune response. The delivery system can be used as a promising platform technology for personalized therapy.

The present invention discloses an intelligent responsive copper-death nanomedicine, its preparation and anti-tumor application. The intelligent responsive copper-death nanomedicine is obtained by loading a copper ion carrier in an intelligent responsive nanocarrier. The intelligent responsive nanocarrier uses copper nanoparticles as the core, and its outer layer is wrapped with a shell of organic mesoporous silica containing X-ray responsive double bonds, and the shell is modified with an acid-responsive polymer. The intelligent responsive nanocarrier has multiple responsive stimulation effects, which can change the charge carried by the drug-carrying system and increase the amount of drug administered into the cell; and has a drug delivery system with good targeting and spatiotemporal controlled release, which can reduce the toxic and side effects of drug molecules on other normal tissues and achieve precise treatment of tumors. The intelligent responsive copper-death nanomedicine can combine the metabolic therapy controlled by copper death with immunotherapy, which will effectively improve tumor resistance, reduce the side effects of radiotherapy on the whole body, and improve the survival rate of patients.

The invention discloses a computer device and a computer readable storage medium for identifying or assisting in identifying transformation of mushroom-like granulomegaly cells. The invention provides a computer device, which comprises a memory, a processor and a computer program stored on the memory, and the processor executes the following steps: S1) data receiving: receiving the percentage of FOXM1 positive cells in skin lesion tissues of a mushroom granuloma (MF) subject; and S2) data output: outputting result information from a computer based on the percentage of the FOXM1 positive cells, wherein the result information indicates whether the mushroom-like granuloma subject is or is candidate to be the transformation of the mushroom-like granuloma cells. Experiments prove that compared with a traditional pathological technology, immunohistochemical staining of FOXM1 can more accurately position large cells and quantify the proportion of the large cells, and subjective bias can be reduced. Therefore, the immunohistochemical staining of the FOXM1 can be used as one of auxiliary technologies for diagnosing the transformation of the mushroom-like granulomegaly cells.

The invention belongs to the technical field of biological medicines, and particularly relates to application of expression of lymph node mast cells to prediction of prognosis survival of tumor patients. The tumor is breast cancer and / or head and neck squamous cell carcinoma. The inventor finds that high-level expression of mast cells in metastatic lymph nodes is related to prognosis survival of tumor patients by exploring functions of the mast cells in the metastatic lymph nodes, and the mast cells can be used as biomarkers for prognosis survival judgment of the tumor patients, so that more valuable information is provided for clinical treatment.